~~<i id='94C3533CAE'><strike id='94C3533CAE'><tt id='94C3533CAE'><pre id='94C3533CAE'></pre></tt></strike></i>~~

00:00

00:00 00:00 LIVE

buffering

Replay

focus

comprehensive

author：fashion 2025-09-28 23:48:34 - browse：91

Novo Nordisk headquarters -- health coverage from STAT — LISELOTTE SABROE/Scanpix/AFP via Getty Images

LONDON — Novo Nordisk said Monday it would acquire the German firm Cardior Pharmaceuticals in a deal worth up to $1.1 billion, picking up additional drug candidates for its pipeline of cardiometabolic medicines.

Cardior focuses on targeting RNA to address the root causes of heart disease. Its lead candidate, known CDR132L, is in Phase 2 development as a treatment for health failure.

The companies did not disclose how much Novo was paying upfront for Cardior and how much would be based on future milestones being achieved. The deal is expected to close in the second quarter.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Virginia high school admissions case could be legal follow
Next article： 3 trends to watch in health tech's hiring outlook for 2024

hotspot

focus

hotspot

focus

DebatesoverCovid'soriginshavebroughtnewattentiontotherisksofgain-of-functionresearch,butnotthebenefi

WSS

Why Marc Tessier

JPM: CVS says Medicare Advantage patients are impacting profits

Florida babysitter arrested over hot car death, authorities say

How a scoliosis diagnosis changed the life of one young dancer

A new deal aims to ramp up use of AI in rehab care decisions

Why the advice to take all your antibiotics may be wrong

focus

comprehensive

hotspot

Drug repurposing or repositioning? The language matters

Ahead of JPM, here's who's profiting most in health care

Biden outlines 'new path' to provide student loan relief after Supreme Court rejection

Feng Zhang CRISPR delivery startup lays off quarter of staff

Malaria cases in Florida and Texas: Here’s what you need to know

Florida babysitter arrested over hot car death, authorities say

In Memoriam: Notable people who died in 2023

U.K. sequencing study surfaces new findings about tumor DNA

Medical records are filled with copy

Grand jury probing Trump's efforts to overturn 2020 election did not meet Friday: Sources

focus

Language on climate change, ESG removed from company website of Montana GOP Senate candidate

Family of Gilgo Beach murder suspect releases statement: 'Devastating time'

How Brent Saunders' Allergan experiment failed

A single drug, study failures leave Anavex with nothing but cash

Why the advice to take all your antibiotics may be wrong

Morgan Health, with ambitious aims, wants you to know it’s still here

hotspot

hotspot

hotspot

focus